12:00 AM
 | 
Sep 10, 2007
 |  BioCentury  |  Strategy

Entering uncharted waters

Boehringer Ingelheim must have liked what it has seen under a deal signed with Ablynx N.V. earlier this year, as it just entered into a broader deal covering 10 targets. The deal is the first under which Ablynx is developing its nanobodies against targets that haven't yet been clinically validated.

"While the money that we have spent and are spending on internal efforts has been focused on clinically validated targets, some of the targets we will work on in this collaboration with Boehringer Ingelheim will focus on novel targets and novel target combinations. This will allow us to explore higher risk and potentially higher value returns for nanobodies," Chairman and CEO Ed Moses told BioCentury.

Nanobodies are single-domain antibody...

Read the full 587 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >